MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis

• Status: Active, not recruiting
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of this study is the quantitative determination of bone-specific microRNAs in the serum of postmenopausal women with osteoporosis during antiresorptive or osteoanabolic therapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Medical University of Vienna
• Collaborator: St. Vincent Hospital, Vienna
• Treatments: Denosumab; Teriparatide

Criteria

Inclusion Criteria:

• Postmenopausal women

• Age 60-80 years

• T-score according to DXA: <-2.5

• indication for osteoporosis therapy according to international guidelines

Exclusion Criteria:

• Diabetes mellitus type 1

• renal insufficiency III-V °

• Cirrhosis hepatis (Child B or higher)

• Chronic alcohol abuse

• rheumatic disease (RA, SpA, SLE)

• Malignancies (<5 years)

• Eating Disorder (anorexia nervosa, bulimia)

• bone-specific pretreatment (DMAB, TPTD, strontium ranelate, SERMs) Bisphosphonate treatment is allowed